Hello JITC Readers,
Welcome to the New Year and one that happens to be of great significance to the journal, as JITC will celebrate its 10th anniversary in 2022. It is humbling to look back on how far JITC has come in the past 10 years, and we are all excited for what the future holds.
Of course, it is the top-caliber articles published in JITC that
have supported the journal’s ascent to being among the most
highly-ranked oncology and immunology journals. This past year was no
exception, and we are highlighting some of the top-most accessed and
downloaded articles from 2021 in this month’s special feature.
The original research spotlighted in this month’s digest
offers new insights on a diverse array of emerging areas in the
immunotherapy field.
Jinzhu Mao and colleagues offer a detailed metagenomic census
of the gut microbiome in patients with hepatobiliary cancers being
treated with immunotherapy, showing that the presence of many
lower-level taxa is not “one-size-fits-all” for clinical benefit.
A novel feedback loop involving CCL18-mediated crosstalk
between tumor-associated macrophages and ovarian carcinoma cells
promoting epithelial-to-mesenchymal transition and other invasive
characteristics is described by Lingli Long et al.
Sub-cytotoxic doses of a metabolite of the topoisomerase I
inhibitor irinotecan were demonstrated to enhance responses to anti-PD-1
via activation of FOXO3 and enhanced tumor infiltration of natural
killer cells by Young Min Chung and colleagues.
Finally, Giuseppe Minniti et al present the results
of a retrospective study indicating that the addition of immunotherapy
to postoperative stereotactic radiosurgery reduces the risk of
leptomeningeal disease for patients with melanoma and non-small cell
lung cancer brain metastases.
Looking forward to what is in store for 2022!
Best,
Pedro J. Romero, MD
Editor-in-Chief, Journal for ImmunoTherapy of Cancer
No comments:
Post a Comment